Express News | Johnson & Johnson Reports 6.8% Passive Stake in Rapport Therapeutics Inc as of Sept 30- SEC Filing
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Rapport Therapeutics Analyst Ratings
Rapport Therapeutics Initiated With a Buy at JonesResearch
JonesTrading Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $42
Promising Growth and Innovation Drive Buy Recommendation for Rapport Therapeutics, Inc.: Focus on RAP-219 and Strategic Collaborations
Jefferies Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $35
Buy Rating Affirmed for Rapport Therapeutics Amid Promising Phase IIa Epilepsy Study and RAP-219's Market Potential
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit
TD Cowen Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics GAAP EPS of -$1.70 Misses by $1.02
Express News | Rapport Therapeutics Ended The Quarter With $336.1M In Cash, Cash Equivalents, And Short-term Investments, Excluding Restricted Cash, Which Is Expected To Fund Operations Through The End Of 2026
Express News | Rapport Therapeutics Q2 2024 GAAP EPS $(1.70) Misses $(0.68) Estimate
Rapport Therapeutics | 10-Q: Quarterly report
Rapport Therapeutics: Runway To Fund Operations Through End of 2026 >RAPP
Rapport Therapeutics 2Q Loss $18.1M >RAPP
Express News | Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
Press Release: Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
No Data
No Data